Helus Pharma CEO to Outline Strategy at Jefferies Healthcare Conference
Event summary
- Eric So, Interim CEO of Helus Pharma, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026.
- The event will be webcast live at 2:35 p.m. EDT.
- Helus Pharma is developing HLP003 (Phase 3) for major depressive disorder and HLP004 (Phase 2) for generalized anxiety disorder.
- HLP003 has received Breakthrough Therapy Designation from the FDA.
The big picture
Helus Pharma's participation in the Jefferies Global Healthcare Conference underscores its push to highlight its proprietary NSAs amid growing demand for innovative mental health treatments. The company's focus on serotonergic agonists positions it in a niche segment of the biopharmaceutical industry, where regulatory approvals and clinical trial outcomes are critical for market differentiation. The strategic emphasis on HLP003 and HLP004 reflects its commitment to addressing unmet needs in depression and anxiety treatment.
What we're watching
- Regulatory Momentum
- Whether the Breakthrough Therapy Designation for HLP003 will accelerate FDA approval timelines.
- Clinical Progress
- The pace at which Phase 3 trials for HLP003 and Phase 2 trials for HLP004 advance.
- Market Positioning
- How Helus Pharma differentiates its NSAs in a competitive mental health treatment landscape.
Related topics